Kiniksa Pharmaceuticals International, plc (KNSA) has a MoatMap StockRank of 94/100 based on Quality (81/100), Value (25/100), and Momentum (76/100) factor scores. The current signal is STRONG BUY. Kiniksa Pharmaceuticals is a commercial-stage biopharma company. While Arcalyst is growing well, the company lacks the diversified platform, deep pipeline, and established cash-flow compounding profile we require for our high-conviction book.
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for patients with debilitating rare diseases. The company's strategic focus on underserved inflammatory and autoimmune conditions provides potential for orphan drug exclusivity, offering a strong competitive moat. Kiniksa aims to become a leader in developing targeted treatments for these specific, high-unmet-need patient populations.
| Price | $47.85 |
| Market Cap | $3.9B |
| P/E (TTM) | 54.10 |
| P/E (Forward) | 28.01 |
| Price/Book | 5.99 |
| Return on Equity | 13.7% |
| Return on Invested Capital | 12.4% |
| Debt/Equity | 1.49 |
| Gross Margin | 54.7% |
| Operating Margin | 13.7% |
| Revenue Growth | 55.5% |
| Free Cash Flow | $118M |
Kiniksa Pharmaceuticals International, plc operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United Kingdom).